S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

$9.00
+0.80 (+9.76%)
(As of 03/28/2024 ET)
Today's Range
$8.00
$9.25
50-Day Range
$6.90
$10.15
52-Week Range
$5.22
$16.60
Volume
14,511 shs
Average Volume
13,546 shs
Market Capitalization
$24.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

Oncternal Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
255.6% Upside
$32.00 Price Target
Short Interest
Healthy
0.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$6,455 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($12.03) to ($11.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

341st out of 938 stocks

Pharmaceutical Preparations Industry

149th out of 417 stocks

ONCT stock logo

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

ONCT Stock Price History

ONCT Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Q4 2023 Oncternal Therapeutics Inc Earnings Call
Oncternal Therapeutics's Earnings: A Preview
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Recap: Oncternal Therapeutics Q4 Earnings
Oncternal Therapeutics: Q4 Earnings Snapshot
Oncternal Therapeutics earnings: here's what to expect
Oncternal Therapeutics Inc ONCT
ONCT Jul 2024 7.500 call
ONCT Apr 2024 2.500 call
Oncternal Therapeutics Announces Reverse Stock Split
Oncternal Therapeutics upgraded to Buy from Hold at Brookline
See More Headlines
Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCT
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$40.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+255.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-39,480,000.00
Net Margins
-5,029.17%
Pretax Margin
-5,029.17%

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
$10.19 per share

Miscellaneous

Free Float
2,474,000
Market Cap
$24.21 million
Optionable
Optionable
Beta
1.27
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

ONCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncternal Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCT, but not buy additional shares or sell existing shares.
View ONCT analyst ratings
or view top-rated stocks.

What is Oncternal Therapeutics' stock price target for 2024?

6 brokers have issued 1 year target prices for Oncternal Therapeutics' shares. Their ONCT share price targets range from $26.00 to $40.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 255.6% from the stock's current price.
View analysts price targets for ONCT
or view top-rated stocks among Wall Street analysts.

How have ONCT shares performed in 2024?

Oncternal Therapeutics' stock was trading at $10.7240 at the beginning of 2024. Since then, ONCT shares have decreased by 16.1% and is now trading at $9.00.
View the best growth stocks for 2024 here
.

When is Oncternal Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ONCT earnings forecast
.

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) posted its earnings results on Thursday, March, 7th. The company reported ($3.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.09) by $0.02. The business had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative trailing twelve-month return on equity of 95.87%. During the same quarter in the previous year, the firm earned ($4.00) earnings per share.

When did Oncternal Therapeutics' stock split?

Oncternal Therapeutics's stock reverse split on the morning of Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).

Who are Oncternal Therapeutics' major shareholders?

Oncternal Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Pasadena Private Wealth LLC (16.96%), Citadel Advisors LLC (1.84%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Chase C Leavitt, Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent and Salim Yazji.
View institutional ownership trends
.

How do I buy shares of Oncternal Therapeutics?

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONCT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners